

Registered charity in England & Wales (1136809) and in Scotland (SC046735)
Registered in England & Wales Company number: 07278507

Reverse Rett

Report and financial statements for the year ended 31 December 2020

Reverse Rett
Trustees' Annual Report
For the year ended 31st December 2020

Reference and Administrative details for the year ended 31st December 2020

Company number 07278507

Charity number 1136809 (England & Wales) and SC046735 (Scotland)

Registered office and operational
address:

Statham Link Suite 1F
Lancastrian Office Centre
Talbot Road
Old Trafford
Manchester
M32 0FP

Trustee/Trustees, who are also directors under company law, who served during the year and up to the date of this report were as follows:

John Sharpe Chair
Helen Simmonds Vice-Chair
Rachael Stevenson*
Andrew J Stevenson*
Monica Coenraads* resigned 08.11.20
Ortensia Martinotti
Catherine McKinney
Kate McMaster
Rita Ross
Neil Buckley
Joanna Snyder
Mwangala Lishomwa *joined 04.05.21

*Trustees who are also Directors of the charitable company. The number of guarantee members is 11.

Key management Rachael Stevenson CEO

Bankers Barclays Bank Leicester LE87 2BB

Independent auditors Slade & Cooper Limited, Beehive Mill, Jersey St, Manchester, M4 6JG

Reverse Rett
Trustees' Annual Report
For the year ended 31st December 2020

The trustees present their report and the audited financial statements for the year ended 31 December 2020. Included within the trustees' report is the directors' report as required by company law.

Reference and administrative information set out on page 1 forms part of this report. The financial statements comply with current statutory requirements, the memorandum and articles of association and the Statement of Recommended Practice - Accounting and Reporting by Charities: SORP applicable to charities preparing their accounts in accordance with FRS 102.

Objectives and activities Mission

Reverse Rett is a patient advocacy and research organisation focused on delivering treatments and a cure for Rett Syndrome to everyone affected.

Objects as set out in the charity's governing document

Reverse Rett **exists to relieve sickness and to preserve health for the public benefit by developing treatments and cures for Rett Syndrome and related *MECP2* disorders**, in particular but not exclusively by:

- funding research projects;
- organising and sponsoring scientific workshops;
- collating information from experts in the field and providing access to it;
and
- increasing general public awareness and knowledge of Rett Syndrome and related *MECP2* disorders.

Main activities undertaken in relation to objects

Children and adults with Rett Syndrome are at the heart of everything we do in line with our mission to deliver treatments and a cure to everyone affected.

Four vital pillars underpin our work:

1. Research

We fund research projects that will lead to better outcomes for children and adults with Rett Syndrome both now and in the future.

2. Advocacy

We advocate for access to treatments and therapies for all affected patients.

3. Outreach

We increase public awareness and knowledge of Rett Syndrome and related *MECP2* disorders so that we can register and contact affected patients who may benefit from emerging treatments.

Reverse Rett
Trustees' Annual Report
For the year ended 31st December 2020

4. Clinical care

We improve clinical care and outcomes for complex UK children and adults with Rett Syndrome whilst disseminating research and clinical best practice information to improve management of all those affected.

Public benefit

The trustees review the aims, objectives, and activities of the charity each year. This report looks at what the charity has achieved and the outcomes of its work in the reporting period. The trustees report the success of each key activity and the benefits the charity has brought to those groups of people that it is set up to help. The review also helps the trustees ensure the charity's aims, objectives and activities remained focused on its stated purposes.

The trustees have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the charity's aims and objectives and in planning its future activities. In particular, the trustees consider how planned activities will contribute to the aims and objectives that have been set.

Reverse Rett
Trustees' Annual Report
For the year ended 31st December 2020

Activities and projects

1. **CIPP Rett Centre, King's College London, £311,137**

In 2019, after comprehensive external peer review, Reverse Rett committed to funding the UK's first specialist Rett Syndrome clinical treatment and research Centre based in London for a period of three years.

The CIPP Rett Centre (formerly CPMRS) was established by Professor Santosh at the Maudsley Hospital and King's College London.

The CIPP Rett Centre is the world's first Centre for personalized medicine in Rett Syndrome that focuses on developing digital health strategies to monitor and manage patients whilst conducting translational research using the HealthTracker platform, providing holistic specialist care and conducting clinical trials.

Reverse Rett has committed to providing core funding to the CIPP Rett Centre at a cost of £998,000 over three years from September 2019-September 2022.

In 2020: Funds delivered to CIPP Rett Centre totaled: £311,137

2. **CIPP Rett Database £12,000**

£12,000 is the pro rata sum (2020) for the software license for the HealthTracker platform. The HealthTracker is an online digital platform, tailored for patients with Rett Syndrome through which families and caregivers can report the patient's symptoms on an ongoing basis.

Data are then analysed on an individual level, to check for changes in the presentation of symptoms and to alert local clinical teams and on a group level, to assess patterns in presentation across the disease group or sub-groups, elucidating wider learning within the field.

3. **MECP2 Duplication Syndrome (MDS) research funding via the Rett Syndrome Research Trust (USA)**

Reverse Rett funds *MECP2* Duplication research through our longstanding partnership with the US based, Rett Syndrome Research Trust (RSRT).

In 2020: Funds delivered to RSRT *MECP2* Duplication projects totaled £25,625

4. **Contributions to the international research program at the Rett Syndrome Research Trust (USA)**

Reverse Rett funds laboratory research through our longstanding partnership with the US based RSRT. Contributions to RSRT lab research were drastically impacted by the impact of the Covid pandemic on charity fundraising.

Reverse Rett
Trustees' Annual Report
For the year ended 31st December 2020

In 2020: Funds delivered to the RSRT international research program totaled £445. These funds were gifted to Reverse Rett by the French organisation, Opé Rett, with respect to RSRT programs in progress at the University of Edinburgh.

5. Clinical trial expenses £11,247

In 2020 we provided on-going support for the UK clinical trial of Cannabidiol sponsored by GW Pharmaceuticals and new support for Anavex for their clinical trial of Anavex 2-73. Reverse Rett provided identification, recruitment and retention services to support both trials. The Clinical trial expenses detailed on p 27 are the costs for patient travel, accommodation, and meal allowances for study visits. These funds were provided to the charity in advance of the study visits and deployed and accounted for accordingly with reports sent back to the sponsors on a quarterly basis.

6. Rett Disorders Alliance £0

Reverse Rett holds the fund for the Rett Disorders Alliance. In 2018, a grant of £5000 was received from the Bolland Charitable Trust by Reverse Rett and designated to the Rett Disorders Alliance fund.

These funds were used for the production and printing of the Health Checklist so that it could be distributed to families and clinicians across the UK as needed.

In 2020: No RDA funds were spent in 2020 and the fund balance is £3,211.

7. Parent 2 Parent program £1050.54

Reverse Rett is a patient advocacy and research organisation and does not formally provide support services to families of patients with Rett Syndrome. The Parent 2 Parent Project was founded in 2012 with support from Roald Dahls Marvelous Children's Charity, to facilitate connections between parent mentors and newly diagnosed families/those in need of additional support.

In 2019, in order to draw new mentors into the program, we held two Discovery Days to enable like-minded families to come together to support and learn from each other. Both meetings were well attended with over 70 participants in London and Edinburgh respectively.

In 2020, two more Discovery Days were planned in Oxford and Warrington. Both had to be cancelled due to the pandemic.

£1050.54 funded an online app which enabled us to switch these in person events to digital events.

In 2020: £1050.54 was spent on switching in person events to digital format so that Discovery Days could go on.

Reverse Rett
Trustees' Annual Report
For the year ended 31st December 2020

8. Governance costs £5640

All charities registered in England and Wales with an income over £500,000 are mandated to have an annual independent audit. These governance costs represent the cost of our 2019 audit and related accountancy services.

9. Support costs (note 7, p 28) £147,914

In 2020, support costs included the above governance costs, office rental, general office costs including phone, internet, printing and postage and staff costs of £95,143.

Staff costs listed here are for CEO (FT), Clinical Trial Lead, (0.5 FTE) Patient Registry Co-ordinator, Finance Officer and Office Administrator/Clinical Trial Co-ordinator.

Staff costs under fundraising costs include: Fundraising Manager (0.5 FTE), Events and Campaigns Co-ordinator (0.5 FTE)

Achievements and performance

The charity's main activities and who it tries to help are described below. All its charitable activities focus on delivering treatments and a cure for Rett Syndrome and are undertaken to further Reverse Rett's charitable purposes for the public benefit.

The main achievements of the charity

Reverse Rett has been at the forefront of UK Rett Syndrome laboratory and clinical research funding for more than a decade. The timeline below shows key milestones demonstrating progress in the field since the reversal experiments of 2007 and the work of Reverse Rett which was launched in 2010.

Over the last ten years, Reverse Rett has been tightly focused on research funding. Change is now within reach. Three human gene therapy clinical trials are firmly on the horizon and as an organisation, we need to do more.

Our first principle is equality; that all patients with Rett Syndrome regardless of age or gender, should have access to emerging treatments and cures.

As well as continuing to fund clinical and laboratory research, we continue to seek out and register as many UK patients as possible, wherever they are, so that we can reach them when treatments which will improve their lives become viable. We are doing this in a few ways, through increased provision of health information, through the Rett Connect program and more. We continue to work in support of UK clinical trials of emerging treatments. Reverse Rett provides core funding to the CIPP Rett Centre, which manages the health the most complex Rett patients in the country, extrapolating and disseminating learnings which can improve the health and quality of life of Rett patients of all ages, internationally.

We are proud of our past achievements and positive about the future unfolding before us.

Below, you can see a timeline of key milestones that show progress in the field since the reversal experiments of 2007 and in the work of Reverse Rett which was launched in 2010.

Reverse Rett
Trustees' Annual Report
For the year ended 31st December 2020

Organisational Achievements

2010

- ✓ Reverse Rett is founded by five parents from the home of now CEO, Rachael Stevenson.

2011

- ✓ Launch of RSRT's international *MECP2* Consortium to combine global efforts to find a tangible way to reverse Rett in humans.

2012

- ✓ Winners of Best New Charity at the Charity Times Awards.
- ✓ Reverse Rett passes first million-dollar mark, delivering over \$1m to Rett Syndrome research mid-year.
- ✓ Winners of Best New Charity at the Just Giving Award.

2013

- ✓ Gene therapy work part funded by Reverse Rett demonstrates reversibility of symptoms of Rett Syndrome in mice.
- ✓ The Rett Syndrome Research Trust (RSRT) launch international Gene Therapy Consortium to compound efforts to drive Gene Therapy for Rett into human trials.
- ✓ Reverse Rett initiates a UK Patient Registry for UK patients with Rett Syndrome to ensure readiness for UK clinical trials.

2014

- ✓ Reverse Rett Co-Founder and CEO joins the Board of Trustees of the Rett Syndrome Research Trust.
- ✓ Reverse Rett begin seed-funding King's College London Research Team at CIPPRD, for work focused on developing new outcome measures (TRIAL Database) for patients with Rett Syndrome under Professor Paramala Santosh.

2015

- ✓ The first family focus groups are held to inform KCL work on the TRIAL database.
- ✓ Reverse Rett international research funding to RSRT passes \$5 million-dollar mark

2016

- ✓ Reverse Rett facilitates the implementation of the first UK clinical trial for an emerging treatment (Sarizotan) for Rett Syndrome, committing funding for a FT Clinical Trials Coordinator based at King's College London.
- ✓ Reverse Rett CEO gives evidence at Ethics Committee hearing for Sarizotan clinical trial

Reverse Rett
Trustees' Annual Report
For the year ended 31st December 2020

2017

- ✓ The Sarizotan clinical trial is launched in Q1 under the leadership of Dr Paramala Santosh at King's College Hospital, London. Reverse Rett providing identification, pre-screening, referral, and retention services.
- ✓ RSRT/AveXis announcement of development of first human clinical trial for gene therapy in patients with Rett Syndrome.

2018

- ✓ Reverse Rett granted full membership of the UK's Association of Medical Research Charities (AMRC).
- ✓ 2nd UK clinical trial for a potential treatment (cannabidiol) launched at three UK trial sites. Reverse Rett providing identification, pre-screening, referral, and retention services.

2019

- ✓ Reverse Rett CEO gives evidence at London Ethics Committee hearing for 3rd UK clinical trial for an emerging treatment for Rett Syndrome.
- ✓ Reverse Rett commits to funding the CIPP Rett Centre for three years. The CIPP Rett Centre is the UK's first dedicated clinical treatment and research centre for children and adults with Rett Syndrome and related disorders and is based in London. The CIPP Rett Centre launched in Sept 2019.

2020

- ✓ 3rd UK clinical trial for a potential treatment (Anavex 2-73) launched at KCL with two other UK trial sites to follow. Reverse Rett providing identification, referral, and retention services.
- ✓ 2021 Three gene therapy companies announce their intention to file IND applications for upcoming clinical trials of gene therapy in Rett Syndrome before the end of 2021.

Reverse Rett
Trustees' Annual Report
For the year ended 31st December 2020

Beneficiaries of our services

The beneficiaries of our services are children and adults with Rett Syndrome and related disorders. Improvements in the symptoms of Rett Syndrome can have far-reaching effects, beyond the individual patient.

There are over 50 reported symptoms of Rett Syndrome; in particular, autonomic disturbances cause significant disruption in the lives of patients and the families who care for them. Amelioration of symptoms such as sleep difficulties, agitation, breathing problems and anxiety can have a significant impact on the lives of patients and families, increasing stress and isolation and impacting the health and well-being of other family members as well as the patient.

At Reverse Rett, we work to enable patients to access emerging treatments through clinical trials as soon as these treatments become available.

Reverse Rett has also been instrumental in facilitating the delivery of UK clinical trials through our work in improving UK clinical provision for patients with Rett, the development of a UK Rett Syndrome Patient Registry, our recruitment, pre-screening and retention support for clinical trials and in 2019, the commitment to fund the CIPP Rett Centre (formerly CPMRS), the UK's first national clinical treatment and research centre for Rett Syndrome based at King's College Hospital.

The CIPP Rett Database which monitors the condition of patients with Rett Syndrome of all ages and stages, all around the UK, gathering anonymized data about disease progression and burden on patients and families which will be an integral component of driving emerging treatments through the regulatory processes.

Both the patient-centred and digital aspects of the work of the CIPP Rett Centre simultaneously generate learning about disease progression and management that is helping patients today, before treatments and a cure become available.

Ultimately, a treatment focused on repairing the underlying cause of the disorder (a lack of mecp2 protein) is needed to significantly reduce or reverse several existing symptoms. Gene therapy trials coming to fruition in 2021-2022, are happening as a direct result of work which Reverse Rett has heavily financially supported over the last decade.

Only time will tell, if and how these gene therapies will be safe and effectively a 'cure' in children and adults with Rett Syndrome. It may be that those who are able to access cures earlier in life recover most effectively. At Reverse Rett, our mission now goes beyond our original goal of curing Rett Syndrome. We need to focus also on enabling access to these emerging therapies for patients with Rett Syndrome of all ages and to ensuring that no one is left behind, when treatments that can drastically improve lives become possible.

Reverse Rett
Trustees' Annual Report
For the year ended 31st December 2020

The Board of Trustees of Reverse Rett would like to thank the following companies, community groups, trusts and individuals who generously supported our work in 2020:

Amanda Adams
Jim Amos
Archerfield Estate
Derek and Jenny Bird
S J Bradbury
Neil and Kate Buckley
Kerry Burroughs
Christopher Cant
Caterpillar Cares Society
Charities Trust
Elisabeth Christopher
Cleeve Vale Rotary Club
Jorge Conde
Core Marketing
Cure for Dylan
Keki Dadiseth
Martin Darby
Mary Davidson
Elly Douglas-Hamilton
DT Impact and Influence
Flowers by Enchantment % Neil Buckley
Stephanie Zinser
David Ford
Sean Forde
Friends of
Holly
Colin
Gordon
Greenery
HG Capital
HR_Inspire
Tim Jones
KDW Financial Planning
Barnaby Lashbrooke
David Lashbrooke
Danielle Ledger
Chris Lowe
Masonic Charitable
Foundation Masons
Internet Lodge 9659
Mersey Valley Golf Country club
committee Masonic Charitable
Foundation
Patricia McCall
Scott and Kate
McMaster
Muchloved
Murphy-Neumann Charity Company
Limited Nicky McBurney Charity
Bootcamp
Kate Noble
Northern Ireland Electricity service charities committee

Peter O'Grady
Peter Meyer Trust
Kelly Phillips
Gillian Prett
Mark Ross
Rita and Gavin Ross
Savills
John and Maureen Sharpe
Clive Sheridan
Matt Smith
Anthony and Joanna Snyder
David H Starbuck
St Michael & All Angels Church
Charlie Talbot
Thrill Collins
Thomas McMaster and Son LTD
Gillian Tree
Myfanwy Tree
McKay Williamson
Alvin and Stephanie Wood

From Grants and trusts

The Pears Foundation
Mrs F B Laurance Charitable Trust
The Munro Foundation
The Patrick & Helena Frost Foundation
The Sumray Trust
The Sylvia Aitken Charitable Trust

Reverse Rett
Trustees' Annual Report
For the year ended 31st December 2020

The Board of Trustees would like to take this opportunity to acknowledge the significant contribution of individuals, companies and community groups who have raised funds for Reverse Rett via online giving facilities such as Just Giving, the Big Give Christmas Challenge and the Reverse Rett Covid Resilience Fund in 2020.

Financial review

2020 was a difficult year for Reverse Rett. Income dropped by 27% compared to 2019 due to the Pandemic and sharp decrease in fundraising events and activities.

Funds which had been set in reserve for 2020 payments to the newly funded CIPP Rett Centre (formerly CPMRS) kept the charity afloat. This meant that we did not have an immediate cashflow problem when the pandemic struck, however, it also meant that we had to restrict any additional research payments over and above the CIPP Rett Centre until the situation stabilized re fundraising.

Here are some examples of the dramatic income changes:

- Just Giving (our main online fundraising platform) income decreased by 24% compared to a 38% increase from 2018-2019. (2020: £163,395 2019: £212,831.89 2018: £163,754)
- London gala income decreased by 34% compared to a 37% increase from 2018-2019 (2020: £91,317; 2019, £138,758; 2018: £101,203.) This year's gala was a virtual as opposed to in person event.
- The Big Give Christmas Challenge is always a virtual event. This year income from this event increased by 11% compared to a 20% increase from 2018-2019 (2020: £82,502, 2019: £74,238, 2018: £62,108)

There are no uncertainties about the charity's ability to continue as a going concern.

Reverse Rett
Trustees' Annual Report
For the year ended 31st December 2020

Reserves policy

Reverse Rett is a parent-driven, patient organisation. Children and adults with Rett Syndrome are at the heart of everything we do. The relentless nature of the condition demands that they should be able to access treatments and cures as quickly as possible.

Funds raised and donated are typically deployed to research projects on a quarterly basis. In 2020, the charity held a greater sum in reserve and reduced contributions to the international research program at RSRT because of the ongoing unpredictability of the fundraising situation during the pandemic and the commitment of £998,000 over three years made to CIPP Rett Centre in September 2019. The charity holds a minimum of 6 months running costs as free reserve. Total funds held at year end was £430,954 of which £85,430 was restricted.

As the fundraising situation continues to stabilize, contributions to the international research program at RSRT have cautiously resumed.

Plans for the future

A Reverse Rett Annual Plan is developed every autumn for the following year. During 2020, the initial annual plan, developed pre- pandemic, was revised in March 2020 to adjust to the evolving situation with Covid.

That plan remained dynamic and was readjusted several times during the year due to new developments which affected in person fundraising capacity.

A plan for 2021 written in autumn of 2020 had to be revised several times due to more changes.

In early 2021, the Reverse Rett Board of Trustees set to work to develop a new long-term strategy for the organisation. The strategy document is entitled 'Change is within Reach,' the Reverse Rett Strategy 2021-2026.

This longer-term plan feeds into the current dynamic annual plan and provides helpful longer-term perspective.

In 2021, Reverse Rett is focused on:

- Ensuring the stability of Reverse Rett throughout 2021 and into 2022, so that we can continue with our mission and vision in the long term.
- Rebuilding fundraising efforts with the on-going constraints of social distancing.

Research:

Continuing to financially support and monitor the CIPP Rett Centre and CIPP Rett Database.
Building international research contributions to RSRT to pre-pandemic levels.
Providing recruitment and retention services for on-going and new clinical trials.

Advocacy:

Providing medical information and resources to families shielding vulnerable family members during the crisis.

Reverse Rett
Trustees' Annual Report
For the year ended 31st December 2020

Outreach:

Increasing general public awareness and knowledge of Rett Syndrome and MECP2 Duplication Syndrome so that we are able to register and contact affected patients who many benefit from emerging treatments.

Directly seeking out under-represented groups and unidentified children and adults with Rett Syndrome for the same reason.

Clinical care:

Improving clinical care and outcomes for complex UK children and adults with Rett Syndrome whilst disseminating research and clinical best practice information to improve medical management of everyone affected.

Structure, governance and management

Reverse Rett is a company limited by guarantee, company number 07278507 incorporated on 9th June 2010. The company was established under a Memorandum of Association which established the objects and powers of the charitable company and is governed under its articles of association.

Reverse Rett is a charity registered in England and Wales, charity number 1136809 and a charity registered in Scotland, charity number SC046735.

Reverse Rett
Trustees' Annual Report
For the year ended 31st December 2020

The first Trustees are those persons notified to Companies House as the first Directors of the Charity. The Charity may by ordinary resolution, appoint a person who is willing to act as a Director and determine the length of rotation in which any additional directors are to retire.

Rachael Stevenson and Andrew Stevenson were involved in the founding of the Charity and remain Trustees to date.

The management of the company is the responsibility of the Trustees who are elected and co-opted under the terms of the Articles of Association.

The trustees are members of the charity, but this entitles them only to voting rights. The trustees have no beneficial interest in the charity.

Members of the charity guarantee to contribute an amount not exceeding £1 to the assets of the charity in the event of winding up. The total number of such guarantees on 31 December 2020 was 10.

The Trustees of the Charity who served during the year ended December 31, 2020 are shown on p1. The Trustees generally meet in person, once annually and via online conferencing on a bi-monthly basis and as needed basis. Since the pandemic started, Trustees have met more frequently and through online face to face meetings via Zoom!

As a parent-driven, patient organisation, Reverse Rett looks first to the Rett Syndrome community to recruit Trustees. The organisation's founding document states in section 19 that

- *A Director must be a natural person aged 16 years or older.*
- *No one may be appointed a Director if he or she would be disqualified from acting under the provisions of article 21.*

Potential trustees are nominated to the Board by one or more of the existing Board members. The validity of the nomination is discussed. The Trustees then vote on whether to approve the membership of the proposed individual.

No other person or external body is permitted to appoint charity trustees.

Induction and training of Trustees is delivered in person through one-to-one contact with the organisation's Chairman, where Trustee's roles and responsibilities are explained and supporting information is sent to the newly recruited Trustee as appropriate.

Reverse Rett
Trustees' Annual Report
For the year ended 31st December 2020

Reverse Rett is a full member of the umbrella organisation, the Association of Medical Research Charities (AMRC). Membership of AMRC requires member organisations to fulfil specific criteria with regards to a high standard of external peer review of proposed research projects and subsequent monitoring.

Detailed information about the established AMRC peer review process at Reverse Rett can be found here. <https://www.reverserett.org.uk/what-we-do/how-we-fund-uk-clinical-research/>

The Board of Trustees of Reverse Rett delegates day to day operational responsibility of the organisation to the CEO, Rachael Stevenson.

In accordance with the charity's Financial Procedures Policy, expenditure of >£20K must be approved by Board Chairman as well as CEO.

The Board of Trustees must review and approve:

- New organisation policies
- Amendments to existing policies
- Funding of new research projects
- Salary increases for CEO and FM

The Reverse Rett Conflict of Interest Policy is signed annually by all Trustees.

Remuneration policy for key management personnel

Two of the charity's Trustees are full-time employees of the organisation and thus receive a salary for their work.

As Founding Trustees of the organisation, Rachael Stevenson and Andrew Stevenson are recused from any Board meetings to discuss the details of their employment at Reverse Rett. Adjustments in remuneration for both parties are decided by the Board of Trustees.

Employment of Directors of the Charity is permitted by Article 6.4.2 of the Memorandum and Articles of Association of the Charity which provides that Directors of the Charity may be employed providing that the majority of Directors do not benefit in this way.

All remaining trustees give their time voluntarily and receive no benefits from the charity. Any expenses reclaimed from the charity by these Trustees are set out in note 10 to the accounts.

Reverse Rett
Trustees' Annual Report
For the year ended 31st December 2020

Related parties and relationships with other organisations

Reverse Rett is a full member of the Association of Medical Research Charities (AMRC)

We work in partnership with the following organisations:

- Rett Syndrome Research Trust (USA) -providing funding for UK based RSRT research projects
- Rett Disorders Alliance UK -working on areas of common interest to benefit the UK Rett community
- Rett UK -UK patient organisation focused on family support for those affected by Rett Syndrome
- Opé Rett
- Gudrun's Rett Syndrome Research Trust
- Israel Rett Syndrome Research and Treatment Foundation

The following are international organisations from whom we have received donations during the 2020 financial year:

Douces Rett Association

Opé Rett

With special thanks to our industry partners:

GW Pharmaceuticals Anavex Life

Sciences Corp

Newron Pharmaceuticals

Taysha Gene Therapies

Novartis Gene Therapies

Risk management

During the annual in person board meeting 2020, the charity trustees considered the major risks to which the charity is exposed.

These include but are not limited to;

- Sudden major decrease in fundraising
- Key personnel changes

Keeping a six-month reserve protects the charity in the short term from a major decrease in fundraising which we have now experienced due to the Covid-19 outbreak.

The potential for key personnel changes will be reviewed on an ongoing basis. The charity is insured against the loss of the Executive Director as recruitment for this post is likely to bring a significantly increased cost for the charity. In 2021, Reverse Rett is working to broaden the management base to deliver more protection for the charity against the loss of key personnel.

Reverse Rett
Trustees' Annual Report
For the year ended 31st December 2020

Fundraising

Reverse Rett is registered with the Fundraising Regulator and considered to be demonstrating commitment to good fundraising practice.

Reverse Rett is committed to following the Fundraising Regulator's Code of Fundraising Practice and the Fundraising Promise and is permitted to use the Fundraising Regulator badge on all fundraising materials.

- There has been no failure to comply with the scheme or the standards referred to in (1) above.
- Reverse Rett's approach to fundraising is laid out in our Fundraising Principles and Fundraising Policies for community fundraising and events which are sent out to all new fundraisers.
- The charity monitors activities carried out on behalf of the charity for the purpose of fundraising through on-going interpersonal relationships with fundraisers and supporters of whom we are aware.
- The number of complaints received by the charity or a person acting on its behalf about activities by the charity or by a person on behalf of the charity for the purpose of fundraising during 2020 was 0.
- In 2018-2019, the charity completed a full GDPR audit to ensure that the privacy of all current and previous donors and fundraisers is secure and that individual consent to hold a limited amount of information re supporters is accounted for.
- Reverse Rett does not engage in telephone, mail or on the street cold solicitations and these actions by another person on behalf of the charity are not permitted.
- The charity has not acted as custodian trustee during the reporting period.

Reverse Rett
Trustees' Annual Report
For the year ended 31st December 2020

Statement of responsibilities of the trustees

The trustees (who are also directors of Frs102 company charity for the purposes of company law) are responsible for preparing the trustees' annual report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the trustees are required to:

- Select suitable accounting policies and then apply them consistently
- Observe the methods and principles in the Charities SORP
- Make judgements and estimates that are reasonable and prudent
- State whether applicable UK Accounting Standards and statements of recommended practice have been followed, subject to any material departures disclosed and explained in the financial statements
- Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the trustees are aware:

- There is no relevant audit information of which the charitable company's auditors are unaware
- The trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditors are aware of that information

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

The trustees' annual report has been approved by the trustees on 14/09/2021
and signed on their behalf by

Helen Simmonds _____
Vice-Chairman

Independent Auditors' Report to the Members and Trustees of Reverse Rett

Opinion

We have audited the financial statements of Reverse Rett (the 'charitable company') for the year ended 31 December 2020, which comprise the Statement of Financial Activities (including the income and expenditure account), the Balance Sheet, the Statement of Cash Flows and the related notes. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice). In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2020, and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The trustees are responsible for the other information. The other information comprises the information included in the trustees' annual report, other than the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the

Independent Auditors' Report to the Members and Trustees of Reverse Rett

other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the trustees' report (incorporating the directors' report) for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the trustees' report has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of our knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the trustees' report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the trustees were not entitled to prepare the financial statements in accordance with the small companies' regime and take advantage of the small companies' exemptions in preparing the Trustees' Annual Report and from the requirement to prepare a strategic report.

Responsibilities of trustees

As explained more fully in the trustees' responsibilities statement set out on page 18, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Independent Auditors' Report to the Members and Trustees of Reverse Rett

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The specific procedures for this engagement and the extent to which these are capable of detecting irregularities, including fraud is detailed below:

- enquiry of management and those charged with governance around actual and potential litigation and claims.
- enquiry of the charity's staff, management and those charged with governance to identify any instances of non-compliance with laws and regulations.
- reviewing minutes of meetings of those charged with governance.
- reviewing financial statement disclosures and testing to supporting documentation to assess compliance with applicable laws and regulations.
- auditing the risk of management override of controls, including through testing journal entries and other adjustments for appropriateness, and evaluating the business rationale of significant transactions outside the normal course of business.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities is available on the Financial Reporting Council's website at: <https://www.frc.org.uk/Our-Work/Audit/Audit-and-assurance/Standards-and-guidance/Standards-and-guidance-for-auditors/Auditors-responsibilities-for-audit/Description-of-auditors-responsibilities-for-audit.aspx>. This description forms part of our auditor's report.

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Chinwe Jennifer Daniel FCCA DChA

Senior Statutory Auditor

for and on behalf of

Slade & Cooper Limited
Statutory Auditors
Beehive Mill
Jersey Street
Manchester, M4 6JG

Date: 24/09/2021

Reverse Rett
Statement of Financial Activities
(including Income and Expenditure account)
for the year ended 31 December 2020

	Note	Unrestricted funds £	Restricted funds £	Total funds 2020 £	Total funds 2019 £
Income from:					
Donations and legacies	3	333,808	23,650	357,458	526,345
Charitable activities:	4	262,700	31,266	293,966	367,320
Total income		596,508	54,916	651,424	893,665
Expenditure on:					
Raising funds	5	110,401	-	110,401	152,538
Charitable activities:	6	531,077	37,923	569,000	477,190
Total expenditure		641,478	37,923	679,401	629,728
Net income/(expenditure) for the year	8	(44,970)	16,993	(27,977)	263,937
Transfer between funds		(16,000)	16,000	-	-
Net movement in funds for the year		(60,970)	32,993	(27,977)	263,937
Reconciliation of funds					
Total funds brought forward		406,494	52,437	458,931	194,994
Total funds carried forward		345,524	85,430	430,954	458,931

The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.

Reverse Rett
Company number 07278507
Balance sheet as at 31 December 2020

	Note	2020		2019	
		£	£	£	£
Fixed assets					
Tangible assets	12		3,504		2,355
Total fixed assets			3,504		2,355
Current assets					
Debtors	13	109,163		106,775	
Cash at bank and in hand		409,978		365,123	
Total current assets		519,141		471,898	
Liabilities					
Creditors: amounts falling due in less than one year	14	(91,691)		(15,322)	
Net assets			430,954		458,931
The funds of the charity:					
Restricted income funds	15		85,430		52,437
Unrestricted income funds	16		345,524		406,494
Total charity funds			430,954		458,931

These accounts are prepared in accordance with the special provisions of part 15 of the Companies Act 2006 relating to small companies and constitute the annual accounts required by the Companies Act 2006 and are for circulation to members of the company.

The notes on pages 26 to 39 form part of these accounts.

Approved by the trustees on 14/09/2021 and signed on their behalf by:

Helen Simmonds (Vice-Chair)

Reverse Rett
Statement of Cash Flows
for the year ending 31 December 2020

	Note	2020 £	2019 £
Cash provided by/(used in) operating activities	19	47,353	144,657
Increase/(decrease) in cash and cash equivalents in the year		44,855	141,759
Cash and cash equivalents at the beginning of the year		365,123	223,364
Cash and cash equivalents at the end of the year		409,978	365,123

Notes to the accounts for the year ended 31 December 2020

1 Accounting policies

The principal accounting policies adopted, judgments and key sources of estimation uncertainty in the preparation of the financial statements are as follows:

a Basis of preparation

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), second edition - October 2019 (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006 and UK Generally Accepted Accounting Practice.

Reverse Rett meets the definition of a public benefit entity under FRS102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note.

Reconciliation with previous Generally Accepted Accounting Practice

In preparing the accounts, the trustees have considered whether in applying the accounting policies required by FRS 102 and the Charities SORP FRS 102 the restatement of comparative items was required. No Restatements were required.

b Preparation of the accounts on a going concern basis

The trustees consider that there are no material uncertainties about the charitable company's ability to continue as a going concern.

The trustees have made no key judgments which have a significant effect on the accounts.

The trustees do not consider that there are any sources of estimation uncertainty at the reporting date that have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities within the next reporting period.

Reverse Rett

Notes to the accounts for the year ended 31 December 2020 (continued)

c Income

Income is recognised when the charity has entitlement to the funds, any performance conditions attached to the item(s) of income have been met, it is probable that the income will be received and the amount can be measured reliably.

Income from government and other grants, whether 'capital' grants or 'revenue' grants, is recognised when the charity has entitlement to the funds, any performance conditions attached to the grants have been met, it is probable that the income will be received and the amount can be measured reliably and is not deferred.

For legacies, entitlement is taken as the earlier of the date on which either: the charity is aware that probate has been granted, the estate has been finalised and notification has been made by the executor(s) to the charity that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the charity has been notified of the executor's intention to make a distribution. Where legacies have been notified to the charity, or the charity is aware of the granting of probate, and the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material.

Income received in advance of a provision of a specified service is deferred until the criteria for income recognition are met.

d Donated services and facilities

Donated professional services and donated facilities are recognised as income when the charity has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use by the charity of the item is probable and that economic benefit can be measured reliably. In accordance with the Charities SORP (FRS 102), general volunteer time is not recognised; refer to the trustees' annual report for more information about their contribution.

On receipt, donated professional services and donated facilities are recognised on the basis of the value of the gift to the charity which is the amount the charity would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

e Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the Bank.

Reverse Rett

Notes to the accounts for the year ended 31 December 2020 (continued)

f Fund accounting

Unrestricted funds are available to spend on activities that further any of the purposes of charity.

Designated funds are unrestricted funds of the charity which the trustees have decided at their discretion to set aside to use for a specific purpose.

Restricted funds are donations which the donor has specified are to be solely used for particular areas of the charity's work or for specific projects being undertaken by the charity.

g Expenditure and irrecoverable VAT

Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably.

Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred.

h Allocation of support costs

Support costs are those functions that assist the work of the charity but do not directly undertake charitable activities. Support costs include back office costs, finance, personnel, payroll and governance costs which support the charity's programmes and activities.

i Operating leases

Operating leases are leases in which the title to the assets, and the risks and rewards of ownership, remain with the lessor. Rental charges are charged on a straight line basis over the term of the lease.

j Tangible fixed assets

Individual fixed assets costing £1,000 or more are capitalised at cost and are depreciated over their estimated useful economic lives on a straight line basis as follows:

Office equipment	25%
Computer equipment	25%

Reverse Rett

Notes to the accounts for the year ended 31 December 2020 (continued)

k Debtors

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

l Cash at bank and in hand

Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

m Creditors and provisions

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

n Financial instruments

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

o Pensions

Employees of the charity are entitled to join a defined contribution 'money purchase' scheme. The charity's contribution is restricted to the contributions disclosed in note 9. There were no outstanding contributions at the year end.

2 Legal status of the charity

The charity is a company limited by guarantee registered in England and Wales and has no share capital. In the event of the charity being wound up, the liability in respect of the guarantee is limited to £1 per member of the charity. The registered office address is disclosed on page 1.

Reverse Rett

Notes to the accounts for the year ended 31 December 2020 (continued)

3 Income from donations and legacies

	Unrestricted £	Restricted £	Total 2020 £
Donations	277,897	21,075	298,972
Grants - Sylvia Aiken Trust	6,000	-	6,000
The Patrick and Helena Trust	10,000	-	10,000
Covid Response and JRS	39,311	-	39,311
Others	600	2,575	3,175
	333,808	23,650	357,458
Total	333,808	23,650	357,458

Income from donations and legacies - previous year

	Unrestricted £	Restricted £	Total 2019 £
<i>Donations</i>	458,619	-	458,619
<i>Grants</i> Charterhouse Charitable Trust	5,000	-	5,000
Sylvia Aiken Trust	8,000	-	8,000
Lawson Trust	-	35,000	35,000
Mazars	-	9,726	9,726
The Patrick and Helena Trust	10,000	-	10,000
	481,619	44,726	526,345
Total	481,619	44,726	526,345

Reverse Rett

Notes to the accounts for the year ended 31 December 2020 (continued)

4 Income from charitable activities

	Unrestricted £	Restricted £	Total 2020 £
The Big Give	82,502	-	82,502
London Event	91,317	-	91,317
MECP2 Fund	665	12,960	13,625
Family events	5,806	-	5,806
Newron Pharmacy	8,874	3,633	12,507
Parent 2 Parent programme	-	14,529	14,529
Gift Aid	71,024	-	71,024
Other income	2,512	144	2,656
	262,700	31,266	293,966
Total	262,700	31,266	293,966

Income from charitable activities - previous year

	Unrestricted £	Restricted £	Total 2019 £
<i>The Big Give</i>	74,238	-	74,238
<i>London Event</i>	138,758	-	138,758
<i>MECP2 Fund</i>	-	54,737	54,737
<i>Family events</i>	13,791	-	13,791
<i>Newron Pharmacy</i>	-	30,000	30,000
<i>Premier Research</i>	-	10,000	10,000
<i>Gift Aid</i>	42,252	-	42,252
<i>Other income</i>	3,544	-	3,544
	272,583	94,737	367,320
Total	272,583	94,737	367,320

5 Cost of raising funds

	2020 £	2019 £
Staff costs	63,456	55,629
Fundraiser's fees	5,139	23,161
Event costs	41,806	73,748
	110,401	152,538
	110,401	152,538

All expenditure on cost of raising funds is unrestricted.

Reverse Rett

Notes to the accounts for the year ended 31 December 2020 (continued)

6 Analysis of expenditure on charitable activities

	Unrestricted £	Restricted £	Total 2020 £
Staff costs	64,253	-	64,253
Transfer to Rett Syndrome Research Trust USA	445	-	445
Travel and accommodation	1,688	-	1,688
Clinical trial expense	-	11,247	11,247
Parent 2 Parent programme	-	1,051	1,051
CPMRS	311,137	-	311,137
MECP2	-	25,625	25,625
Governance costs (see note 7)	5,640	-	5,640
Support costs (see note 7)	147,914	-	147,914
	<hr/>	<hr/>	<hr/>
	531,077	37,923	569,000
	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>

Analysis of expenditure on charitable activities - previous year

	Unrestricted £	Restricted £	Total 2019 £
<i>Staff costs</i>	<i>53,620</i>	<i>-</i>	<i>53,620</i>
<i>Transfer to Rett Syndrome Research Trust USA</i>	<i>141,632</i>	<i>64,463</i>	<i>206,095</i>
<i>Travel and accommodation</i>	<i>14,161</i>	<i>-</i>	<i>14,161</i>
<i>Kings College Grant</i>	<i>6,030</i>	<i>-</i>	<i>6,030</i>
<i>Clinical trial expense</i>	<i>2,662</i>	<i>37,411</i>	<i>40,073</i>
<i>Rett disorders alliance</i>	<i>-</i>	<i>3,211</i>	<i>3,211</i>
<i>Parent 2 Parent programme</i>	<i>-</i>	<i>3,845</i>	<i>3,845</i>
<i>CPMRS</i>	<i>12,789</i>	<i>-</i>	<i>12,789</i>
<i>Governance costs</i>	<i>6,400</i>	<i>-</i>	<i>6,400</i>
<i>Support costs</i>	<i>130,966</i>	<i>-</i>	<i>130,966</i>
	<hr/>	<hr/>	<hr/>
	<i>368,260</i>	<i>108,930</i>	<i>477,190</i>
	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>

Reverse Rett

Notes to the accounts for the year ended 31 December 2020 (continued)

7 Analysis of governance and support costs

	Support £	Governance £	Total 2020 £
Office rental cost	5,653	-	5,653
Staff costs	96,695	-	96,695
Office costs	39,045	-	39,045
Audit fees	-	3,600	3,600
Accountancy services	-	2,040	2,040
Legal and professional	3,682	-	3,682
Advertising and marketing	2,839	-	2,839
	147,914	5,640	153,554
	147,914	5,640	153,554

8 Net income/(expenditure) for the year

	2020 £	2019 £
This is stated after charging/(crediting):		
Depreciation	1,349	543
Operating lease rentals:		
Property	-	7,572
Other	2,568	2,568
Auditor's remuneration - audit fees	3,000	3,480
Auditor's remuneration - accountancy fees	1,600	1,920
	1,600	1,920
	1,600	1,920

Reverse Rett

Notes to the accounts for the year ended 31 December 2020 (continued)

9 Staff costs

Staff costs during the year were as follows:

	2020 £	2019 £
Wages and salaries	198,922	174,643
Social security costs	18,126	14,263
Pension costs	7,356	5,897
	<hr/>	<hr/>
	224,404	194,803
	<hr/> <hr/>	<hr/> <hr/>
Allocated as follows:		
Cost of raising funds	63,456	55,629
Charitable activities	64,253	53,620
Support costs	96,695	85,554
	<hr/>	<hr/>
	224,404	194,803
	<hr/> <hr/>	<hr/> <hr/>

No employees has employee benefits in excess of £60,000 (2019: Nil).

The average number of staff employed during the period was 7 (2019: 6).

The key management personnel of the charity comprise the trustees and the Chief Executive Officer. The total employee benefits of the key management personnel of the charity were £53,040 (2019: £38,234).

10 Trustee remuneration and expenses, and related party transactions

Two of the trustees Rachael Stevenson (Chief Executive) and Andrew Stevenson (Director) received remuneration totalling £91,831 (2019: £90,438).

No trustee received travel and subsistence expenses during the year. (2019:nil).

Aggregate donations from related parties were £44,650. (2019: £25,550).

There are no donations from related parties which are outside the normal course of business and no restricted donations from related parties.

The Chief Executive and a director of Reverse Rett, Rachael Stevenson is on the Board of Rett Syndrome Research Trust USA. Monica Coenraads who is also a director of Reverse Rett sits on the Board of Rett Syndrome Research Trust USA.

Reverse Rett made charitable grant to Rett Syndrome USA of £445 this year. (2019: £206,095).

No trustee or other person related to the charity had any personal interest in any contract or transaction entered into by the charity, including guarantees, during the year (2019: nil).

Reverse Rett

Notes to the accounts for the year ended 31 December 2020 (continued)

11 Corporation tax

The charity is exempt from tax on income and gains falling within Chapter 3 of Part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992 to the extent that these are applied to its charitable objects. No tax charges have arisen in the charity.

12 Fixed assets: tangible assets

Cost	Computer equipment £
At 1 January 2020	5,027
Additions	2,498
Disposals	-
	<hr/>
At 31 December 2020	7,525
	<hr/> <hr/>
Depreciation	
At 1 January 2020	2,672
Charge for the year	1,349
Disposals	-
	<hr/>
At 31 December 2020	4,021
	<hr/> <hr/>
Net book value	
At 31 December 2020	3,504
	<hr/> <hr/>
<i>At 31 December 2019</i>	<i>2,355</i>
	<hr/> <hr/>

Reverse Rett

Notes to the accounts for the year ended 31 December 2020 (continued)

13 Debtors

	2020 £	2019 £
Other debtors	6,300	14,980
Prepayments and accrued income	26,672	26,876
Gift aid debtor	25,956	15,784
Big Give debtor	50,235	49,135
	<hr/>	<hr/>
	109,163	106,775
	<hr/> <hr/>	<hr/> <hr/>

14 Creditors: amounts falling due within one year

	2020 £	2019 £
Trade creditors	2,351	1,277
Other creditors and accruals	78,956	8,071
Taxation and social security costs	10,384	5,974
	<hr/>	<hr/>
	91,691	15,322
	<hr/> <hr/>	<hr/> <hr/>

Reverse Rett

Notes to the accounts for the year ended 31 December 2020 (continued)

15 Analysis of movements in restricted funds

	Balance at 1 January 2020 £	Income £	Expenditure £	Transfers £	As at 31 December 2020 £
<i>MECP2</i>					
Duplication	2,680	34,035	(25,625)	-	11,090
Rett disorder alliance	4,861	-	-	-	4,861
Use in Farringdon	200	-	-	-	200
Parent 2 Parent Programme Clinical Research Funds	7,107	14,529	(1,051)	-	20,585
	37,589	6,352	(11,247)	16,000	48,694
Total	52,437	54,916	(37,923)	16,000	85,430

Previous reporting period	Balance at 1 January 2019 £	Income £	Expenditure £	Transfers £	31 December 2019 £
<i>MECP2</i>					
Duplication	2,680	64,463	(64,463)	-	2,680
Rett disorder alliance	3,072	-	(3,211)	5,000	4,861
Use in Parent 2 Parent Programme Clinical	200	-	-	-	200
	10,952	-	(3,845)	-	7,107
	-	75,000	(37,411)	-	37,589
Total	16,904	139,463	(108,930)	5,000	52,437

Name of restricted fund	Description, nature and purposes of the fund
------------------------------------	---

MECP2	The <i>MECP2</i> Duplication Fund at Reverse Rett is a restricted fund. The fund exclusively supports projects devoted to the study and means of treatment of <i>MECP2</i> Duplication/Triplication Syndrome. 100% of funds raised and contributed to Reverse Rett by families of children with <i>MECP2</i> Duplication Syndrome and their supports in the UK are committed to <i>MECP2</i> Duplication projects via RSPT US.
-------	--

Reverse Rett

Notes to the accounts for the year ended 31 December 2020 (continued)

Parent 2 Parent	<p>Reverse Rett Parent 2 Parent offers grants parent to parent support as a resource to families of newly diagnosed or struggling children with Rett Syndrome and related <i>MECP2</i> disorders. Through a one to one 'match', experienced parents provide emotional support to families and assist them in finding information and resources.</p> <p>Through the project, Reverse Rett provides on-going training and support for mentors and materials for both mentor and mentee. Communication between both parties is facilitated by Reverse Rett in the first six weeks of contact and thereafter as required.</p> <p>Please find more information here: http://www.reverserett.org.uk/get-involved/get-connected/</p>
Clinical Research Fund	<p>This is a designated fund which will support UK based clinical research and the implementation of treatment for Rett Syndrome and related <i>MECP2</i> Disorders in the UK.</p>

16 Analysis of movement in unrestricted funds

	Balance at 1 January 2020 £	Income £	Expenditure £	Transfers £	As at 31 December 2020 £
General fund	406,494	596,508	(641,478)	(16,000)	345,524
	406,494	596,508	(641,478)	(16,000)	345,524
	406,494	596,508	(641,478)	(16,000)	345,524
<i>Previous reporting period</i>	<i>Balance at 1 January 2019 £</i>	<i>Income £</i>	<i>Expenditure £</i>	<i>Transfers £</i>	<i>As at 31 December 2019 £</i>
General fund	178,090	754,202	(520,798)	(5,000)	406,494
	178,090	754,202	(520,798)	(5,000)	406,494
	178,090	754,202	(520,798)	(5,000)	406,494

Name of unrestricted

Description, nature and purposes of the fund

General fund The free reserves after allowing for all designated funds

Reverse Rett

Notes to the accounts for the year ended 31 December 2020 (continued)

17 Analysis of net assets between funds

	General fund £	Designated funds £	Restricted funds £	Total £
Tangible fixed assets	3,504	-	-	3,504
Net current assets/(liabilities)	342,020	-	85,430	427,450
Total	345,524	-	85,430	430,954

18 Operating lease commitments

The charity's total future minimum lease payments under non-cancellable operating leases is as follows for each of the following periods:

	Property		Equipment	
	2020 £	2019 £	2020 £	2019 £
Less than one year	-	7,572	2,568	2,568
One to five years	-	8,834	6,870	9,438
	-	16,406	9,438	12,006

19 Reconciliation of net movement in funds to net cash flow from operating activities

	2020 £	2019 £
Net income/(expenditure) for the year	(27,977)	263,937
Adjustments for:		
Depreciation charge	1,349	543
Decrease/(increase) in debtors	(2,388)	(83,114)
Increase/(decrease) in creditors	76,369	(36,709)
Net cash provided by/(used in) operating	47,353	144,657